Note: Selected releases translated to English. To see all Nasdaq regulatory releases, see Swedish press releases.
ExpreS2ion Biotech Holding AB: Publication of interim report for January – September 2019
ExpreS[2]ion Biotech Holding AB (“ExpreS[2]ion”) hereby publishes its interim report for the period January – September 2019. The report is available as an attached document to this press release and on the Company’s website (www.expres2ionbio.com). Below is a summary of the report.
Read moreBreakthrough: ExpreS2ion launches first unique cell line for enhanced efficacy of vaccines and immunotherapy
After several years of research and development, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces the launch of a new tailormade S2 cell line, HighMan-S2™. This is the first member of ExpreS2ion’s new functionally modified S2 product line, GlycoX-S2™, which utilises and expands the advantages of the ExpreS2 platform.
ExpreS2ion’s joint venture AdaptVac receives Danish InnoBooster grant of 1.2 MSEK for for breast cancer studies in dogs
ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces today that its joint venture company AdaptVac ApS (“AdaptVac”) has been awarded an InnoBooster grant by the Danish Innovation Foundation worth 0.8 MDKK (approx. 1.2 MSEK). The grant provides further resources for the development of a safe and effective treatment for dogs diagnosed with DER2+ cancer. In addition to…
Read moreExpreS 2 ion secures SEK 8 million in bridge financing to facilitate further growth
ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that the Company is increasing its working capital by securing a combination of a bridge loan and a loan facility of up to SEK 8 million in total. This will enable ExpreS2ion to further expand its business activities in line with the growth numbers reported for Q1 and Q2…
Read moreNew date for publication of interim report 3
Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that the Company will publish its interim report for the period January – September 2019 on November 14th, 2019, instead of the previously scheduled November 21st, 2019. The aim of the advanced publication is to coordinate the release with the Company’s planned participation in a major public investor…
Read moreExpreS2ion receives 1.6 MSEK order in development program for next-generation malaria vaccine
ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that it has received a 1.6 MSEK order to perform development work as part of a Wellcome Trust funded malaria vaccine project. The project is led by Jenner Institute at the University of Oxford, and the goal is to create a…
Read moreExpreS 2 ion Biotech Holding AB: Publication of interim report for January – June 2019
ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby publishes its interim report for the period January – June 2019. The report is available as an attached document to this press release and on the Company’s website (www.expres2ionbio.com). Below is a summary of the report.
Read moreExpreS2ion’s licensee Institut Virion\Serion launches the first in vitro diagnostic product based on the ExpreS2-platform
ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces the Company’s entry on the market for in vitro diagnostic (IVD) applications through its Germany-based licensee Institut Virion\Serion GmbH (“Virion”). Virion is now launching a unique Zika NS1 viral antigen produced in the ExpreS2 platform, and over the next 18 months Virion will increase its offering of products using…
Read moreExpreS2ion licenses groundbreaking CRISPR/Cas9 gene editing technology from ERS Genomics
ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces the signing of a non-exclusive license agreement with ERS Genomics, providing ExpreS2ion with the right to use and commercialise products, for its own use or together with customers or partners, based on the highly efficient CRISPR/Cas9 gene editing technology. This will enable the Company to offer a whole new…
Read moreChange of Certified Adviser to Svensk Kapitalmarknadsgranskning AB
ExpreS2ion Biotech Holding AB (publ) has entered into an agreement with Svensk Kapitalmarknadsgranskning AB (“SKMG”) regarding Certified Adviser services. SKMG will be appointed as Certified Adviser on the 1st of July 2019. Until the 1st of July 2019, Sedermera Fondkommission will continue to act as Certified Adviser for the Company.
Read moreReport from ExpreS2ion Biotech Holding AB’s (publ) annual general meeting
This is an unofficial translation of a report from the Annual General Meeting in ExpreS2ion Biotech Holding AB, originally drafted in Swedish. In case of any discrepancies between the Swedish original and this translation, the Swedish version shall prevail. Today, on May 23, 2019, the annual general meeting of ExpreS2ion Biotech Holding AB (publ) was…
Read moreExpreS2ion Biotech Holding AB: Publication of interim financial report for January – March 2019
ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby publishes financial report for the period of January – March 2019. The report is available as an attached document to this press release and on the Company’s website (www.expres2ionbio.com). Below is a summary of the report.
Read moreExpreS2ion Biotech Holding AB: Publication of Annual Report for the fiscal year 2018
The Board of Directors and the Chief Executive Officer of ExpreS2ion Biotech Holding AB hereby publishes the Annual Report for the fiscal year 2018. The Annual Report and the accompanying Auditor’s Report is available on the Company’s website (www.expres2ionbio.com).
Read moreCorrection: Notice to Annual General Meeting in ExpreS2ion Biotech Holding AB (publ)
This is an unofficial translation of a notice to the Annual General Meeting in ExpreS2ion Biotech Holding AB, originally drafted in Swedish. In case of any discrepancies between the Swedish original and this translation, the Swedish version shall prevail. The shareholders of ExpreS2ion Biotech Holding AB (publ), 559033-3729, are hereby invited to attend the Annual…
Read moreNotice to Annual General Meeting in ExpreS2ion Biotech Holding AB (publ)
This is an unofficial translation of a notice to the Annual General Meeting in ExpreS2ion Biotech Holding AB, originally drafted in Swedish. In case of any discrepancies between the Swedish original and this translation, the Swedish version shall prevail. The shareholders of ExpreS2ion Biotech Holding AB (publ), 559033-3729, are hereby invited to attend the Annual…
Read moreReport from Extraordinary General Meeting in ExpreS2ion Biotech Holding AB (publ)
On the 19th of March 2019, an Extraordinary General Meeting in ExpreS2ion Biotech Holding AB was held. Below is a summary of the decisions that were taken. All decisions were taken with required majority.
Read moreNotice to Extraordinary General Meeting in ExpreS2ion Biotech Holding AB (publ)
The shareholders of ExpreS2ion Biotech Holding AB, 559033-3729, are hereby invited to attend an Extraordinary General Meeting on Tuesday, March 19, 2019, at 10.00 at c/o Mazars SET, Terminalgatan 1, in Helsingborg.
Read moreExpreS2ion conducts a directed share issue to accelerate the development of the company
ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces that the Company is conducting a directed share issue to a number of existing shareholders and strategic investors of initially approx. SEK 8 million, with attached consideration-free warrants, which in later stages can provide the Company with a further approx. SEK 9.6 million. The directed share issue is…
Read moreExpreS2ion Biotech Holding AB: Publication of financial report for January – December 2018
ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby publishes financial report for the period of January – December 2018. The report is available as an attached document to this press release and on the Company’s website (www.expres2ionbio.com). Below is a summary of the report.
Read moreExpreS2ion’s joint venture AdaptVac receives SEK 3.6 million grant for vaccine to reduce antibiotic usage in pigs
ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that its joint venture AdaptVac ApS (“AdaptVac”) has been awarded approx. SEK 3.6 million by the Danish Innovation Foundation for its participation in a vaccine project aimed at preventing post-weaning diarrhea (PWD), a major cause of antibiotic use in the swine industry.
Read moreExpreS2ion co-publishes positive phase I placental malaria vaccine results from the PlacMalVac consortium
ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that the placental malaria vaccine (PlacMalVac) consortium, of which ExpreS2ion is part, has announced successful phase I clinical study results. The PAMVAC vaccine, manufactured using the ExpreS2 platform, was demonstrated to be safe, well-tolerated and to elicit specific antibody responses in all participants.
Read moreExpreS2ion’s joint venture AdaptVac receives grants for two new projects: cardiovascular disease and breast cancer in dogs
ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that its joint venture AdaptVac ApS (“AdaptVac”) has received DKK 2.2 million (SEK 3.2 million) in funding from the Danish Innovation Foundation for two new vaccine development projects: cardiovascular disease (CVD) in humans and HER2+ breast cancer in dogs. The HER2+ dog project will also be used as preclinical…
Read moreExpreS2ion’s patent and research partner publishes malaria vaccine breakthrough in Nature
ExpreS2ion Biotech Holding AB (“ExpreS2ion") announces the publication of the first visual image of the molecular ’key’ the deadliest malaria parasite uses to enter human blood cells in Nature. The publication was authored by an international team, including scientists from ExpreS2ion, led by the Walter and Eliza Hall Institute of Medical Research (“WEHI”). This breakthrough…
Read moreExpreS2ion Biotech Holding AB: Publication of financial report for January – September 2018
ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby publishes the financial report for the period of January – September 2018. The report is available as an attached document to this press release and on the Company’s website (www.expres2ionbio.com). Below is a summary of the report.
Read moreExpreS2ion announces positive Phase I/IIa malaria vaccine trial results by The Jenner Institute, University of Oxford
Horsholm, Denmark, October 31 2018 – Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that The Jenner Institute of the University of Oxford presents positive results from its Phase I/IIa clinical studies with their RH5.1 blood-stage malaria vaccine at a scientific meeting in New Orleans. The vaccine, developed and manufactured using ExpreS2ion’s ExpreS2 platform, was shown…
Read moreExpreS2ion announces upcoming presentation of Phase I/IIa malaria vaccine trial results by Jenner Institute
Horsholm, Denmark, October 18, 2016 – Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that its collaboration partner, Jenner Institute of the University of Oxford, will present the results from the Phase I/IIa clinical studies of its RH5.1 blood stage malaria vaccine at the annual American Society of Tropical Medicine and Hygiene (ASTMH) meeting on the 31st…
Read moreExpreS2ion’s joint venture, AdaptVac, receives notice of allowance in the U.S. for its breast cancer vaccine patent
ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that its joint venture AdaptVac has received a notice of allowance in the USA for its patent application covering its novel vaccine treatment for HER2-positive breast cancer. This means that the patent is expected to be issued shortly, which is an important step…
Read moreExpreS2ion’s own Zika virus antigen products included in agreement with U.S.-based Integrated BioTherapeutics
ExpreS2ion Biotech Holding AB’s fully owned subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) announces that it has amended its Research & Commercial License Agreement with U.S.-based partner and licensee Integrated BioTherapeutics (“IBT”) to include own ExpreS2-based products, initially a number of Zika virus antigens.
Read moreExpreS2ion Biotech Holding AB: Publication of financial report for January – June 2018
ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby publishes the financial report for the period of January – June 2018. The report is available as an attached document to this press release and on the Company’s website (www.expres2ionbio.com). Below is a summary of the report.
Read moreExpreS2ion and GenIbet sign collaboration agreement for vaccine development and GMP production
ExpreS2ion Biotech Holding AB’s fully owned subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) has signed a collaboration agreement regarding vaccine development and GMP (Good Manufacturing Practice) manufacturing with its Portuguese partner GenIbet Biopharmaceuticals, S.A. (“GenIbet”). The agreement strengthens ExpreS2ion’s position as a full-service provider from discovery up to early clinical development.
Read moreReport from ExpreS2ion Biotech Holding AB’s (publ) annual general meeting
Today, May 24th, 2018, the annual general meeting of ExpreS2ion Biotech Holding AB (publ) was held. A summary of the decisions that were made follows below. All decisions were taken with required majority.
Read moreExpreS2ion’s core platform patent allowed in Canada
ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that the Company’s patent application “Improved Protein Expression System”, that covers the entire ExpreS2 platform, has been allowed in Canada and will be granted with expiry June 12, 2029.
Read moreExpreS2ion Biotech Holding AB: Publication of financial report for January – March 2018
ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby publishes financial report the period of January – March 2018. The report is available as an attached document to this press release and on the Company’s website (www.expres2ionbio.com). Below is a summary of the report.
Read moreExpreS2ion Biotech Holding AB: Publication of Annual Report for the fiscal year 2017
The Board of Directors and the Chief Executive Officer of ExpreS2ion Biotech Holding AB hereby publishes the Annual Report for the fiscal year 2017. The Annual Report and the accompanying Auditor’s Report is available on the Company’s website (www.expres2ionbio.com).
Read moreExpreS2ion’s U.S. partner Integrated BioTherapeutics launches first ExpreS2-based research product
ExpreS2ion Biotech Holding AB’s fully owned subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) announces that its U.S.-based partner and licensee Integrated BioTherapeutics (“IBT”) has initiated sales and marketing of its first ExpreS2-based product. The product, an Ebola virus glycoprotein, is marketed as a part of IBT’s high-quality research protein portfolio and can be used in the development…
Read moreExpreS2ion Biotech Holding AB: Last day of trading in BTA
In February 2018, ExpreS2ion Biotech Holding AB (“ExpreS2ion”) conducted a rights issue of shares in which the public also were given the opportunity to subscribe for shares. Through the rights issue, 2,400,403 shares were issued. Last day of trading in BTAs (paid subscription share) is March 15th, 2018 and stop date is March 19th, 2018.
Read moreExpreS2ion’s rights issue oversubscribed
Hørsholm, Denmark, March 2nd, 2018 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces that the Company’s rights issue of approximately SEK 19.2 million in order to finance investments in several parts of the core business and also to supply additional working capital for future investments in new business opportunities for both ExpreS2ion and AdaptVac, has…
Read moreExpreS2ion Biotech Holding AB announces start of subscription period in the rights issue
Today, on February 8th, 2018, the subscription period in ExpreS2ion Biotech Holding AB’s (“ExpreS2ion”) rights issue, starts. The rights issue is also open to the public. The subscription period ends on February 27th, 2018. A fully subscribed rights issue provides ExpreS2ion with approximately SEK 19.2 million before issuing costs. Beforehand, the company has agreed on…
Read moreExpreS2ion publishes memorandum in relation to the preferential rights issue
Hørsholm, Denmark, February 7th, 2018 – ExpreS2ion Biotech Holding AB (”ExpreS2ion”) hereby publishes its memorandum in Swedish and English in relation to the preferential rights issue, for which the subscription period starts on February 8th. 2018.
Read moreExpreS2ion resolves on a preferential rights issue to accelerate the Company’s development
Hørsholm, Danmark, January 16, 2018 – ExpreS2ion Biotech Holding AB (”ExpreS2ion”) announces that the Board has decided, pursuant to the authorisation granted by an Extraordinary General Meeting, to carry out a preferential rights issue with the aim to accelerate the Company's development. The preferential rights issue comprises a maximum of 2,400,403 shares with a subscription…
Read moreExpreS2ion’s core platform patent allowed in India
Hørsholm, Denmark, December 28, 2017 – Today, ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that the company’s patent application “Improved Protein Expression System”, that covers the entire ExpreS2 platform, has been allowed in India and will be granted with expiry June 12, 2029.
Read more